The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.
Aviad Hadar, Jonathan David, Nadav Shalit, Leor Roseman, Raz Gross, Ben Sessa, Shaul Lev-Ran
Journal of Psychoactive Drugs 2023 DOI: 10.1080/02791072.2021.2022254 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Bibliometric analysis Peer reviewed |
|---|---|
| Sample size | 100 |
| Population | Top-cited articles on psychedelic research |
| Topics | Ayahuasca LSD MDMA Psilocybin |
| Keywords | Bibliometric analysis Drug–psychotherapy combination Psychedelics Research evaluation Scientometrics |
| Citations | 93 |
| Key points | The top-cited 100 articles on psychedelic research were cited between 82 and 668 times, with 54% published in the past decade (2010-2020), and the UK, USA, Switzerland, Spain, and Brazil leading the field. |
Abstract
Psychedelics were used in the treatment of psychiatric conditions prior to their prohibition in the late 1960s. In the past three decades, there is a revived research interest in the therapeutic potential of psychedelic drugs with expected FDA approvals for treatment of various conditions. Given the exponential scientific growth of this field, we sought to characterize, analyze, and visualize trends in its top-cited articles. Bibliometric analyses are quantitative approaches to characterize a scientific field, including evaluation of the impact of academic literature. The bibliometric analysis and visualizations were conducted with R-tools for comprehensive science mapping. The top-cited 100 articles were cited between 82 and 668 times (median 125; mean 158). Fifty-four percent of the T100 articles were produced in the past decade (2010-2020). Network and author impact analysis highlighted key figures and primary collaboration networks within the top 100 publications. UK, USA, Switzerland, Spain, and Brazil lead the field. Results are discussed in terms of research growth, access, diversity, and the distribution of knowledge and experience in the field. These aggregated data and insights on the second wave of psychedelic research facilitate research evaluation, data-driven funding policies, and a practical map for researchers and clinicians entering the field.
Citations in the library
Cited by 77
- Australia to prescribe MDMA and psilocybin for PTSD and depression in world first Nature July 13, 2023
- A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology November 1, 2022
- High ventilation breathwork practices: An overview of their effects, mechanisms, and considerations for clinical applications. Neuroscience & Biobehavioral Reviews December 1, 2023
- Psilocybin’s effects on cognition and creativity: A scoping review Journal of Psychopharmacology July 1, 2023
- Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression Psychoactives April 16, 2024
and 72 more in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
and 14 more in the library